Compare Becton Dickinson and Co (BDX) vs HSBC Holdings plc (HSBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs HSBC Holdings plc — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while HSBC Holdings plc trades at $99.75 (market cap $337.30B). The key difference: HSBC Holdings plc is far larger — about 8.1× Becton Dickinson and Co's market cap, and HSBC Holdings plc pays the higher dividend (3.78%). Which is the better fit depends on your goals.
| BDX | HSBC | |
|---|---|---|
Market Cap | $41.51B | $337.30B |
Sector | Health | Technology |
52-Week High | $185.39 | $99.25 |
52-Week Low | $135.49 | $61.30 |
Enterprise Value | $57.97B | — |
Dividend Yield | 2.79% | 3.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
HSBC trades at $98.09, down 1.01% today but near its 52-week high of $99.47. Technical indicators show a bullish trend with strong moving average support. The bank reported $71.02B revenue and $22.29B net income for 2025, maintaining a robust 30.81% net margin. Recent news highlights strategic moves including AI partnerships with Google Cloud and potential divestitures of non-core units like its Turkey business.
HSBC presents a balanced investment case with steady profitability and strategic refocusing, but faces risks from global economic sensitivity and regulatory challenges. Analyst consensus is mixed with 38% buy ratings, suggesting cautious optimism amid execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →
